The μEncapsulator System from Dolomite Bio is a complete solution for high throughput encapsulation of individual cells into picoliter droplets. Ideal for profiling natively-paired T-cell receptors (TCRs), this compact, flexible and modular system can process up to 300,000 cells in 15 minutes.
Dolomite Bio, a brand of Blacktrace Holdings Limited, celebrated the first anniversary of its launch on March 1st, marking the end of a fruitful year in business. This biology-focused brand, a spin out from sister company Dolomite Microfluidics, is dedicated to the development of innovative products for high throughput single cell encapsulation.
Dolomite Bio has launched a new Injection Valve and Sample Loop for single cell RNA sequencing workflows. This option enables straightforward, gentle introduction of evenly distributed mRNA capture beads into the company’s RNA-Seq System for individual encapsulation of cells.
Researchers at The Institute of Cancer Research (ICR), London, are taking advantage of the single cell encapsulation capabilities of Dolomite Bio’s Single Cell RNA-Seq System to investigate resistance mechanisms in prostate cancer. Karolina Nowakowska, a PhD student at The Institute of Cancer Research, explained: “Our team is focused on studying treatment resistance in prostate cancer patients, looking at the biochemical mechanisms responsible.
Dolomite Bio’s Single Cell RNA-Seq System is helping researchers at the University of Helsinki to investigate autoimmune diseases. Focusing on gastrointestinal conditions – such as coeliac disease and inflammatory bowel disease – the Molecular Genetics of Immunological Diseases group is using the system to study T-cell activation and response at the single cell level.